CS
MRNA icon

Candriam SCA’s Moderna MRNA Stock Holding History

Candriam SCA’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-38,214,700
Closed -$27.1M – 834
2020
Q3 		$27.1M Buy
+38,214,700
New +$2.66B 0.25% 99

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Candriam SCA's MRNA Position: Q1 2026 in Review

Candriam SCA increased its Moderna (MRNA) stake by 0.8% in Q1 2026, buying an estimated $85.2K and bringing the position to 230,824 shares worth $11.7M. The position accounts for 0.06% of the portfolio, ranked #254.

Candriam SCA first reported a position in MRNA in Q2 2020 and has held it in 23 quarters since. The position peaked at $80.3M in Q3 2021. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Candriam SCA held 230,824 shares of Moderna worth $11.7M as of Q1 2026.
  • Candriam SCA bought 1,826 Moderna shares in Q1 2026, an estimated $85.2K.
  • Moderna made up 0.06% of Candriam SCA's portfolio in Q1 2026, its #254 holding.
  • Candriam SCA first reported a position in Moderna in Q2 2020 and has held it in 23 quarters since.
  • Candriam SCA's Moderna position peaked at $80.3M in Q3 2021.
  • 723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.